Concepedia

Mark A. Deeg

MA

Statistics

Publications

61

Citations

5.1K

H-Index

33

Active since

1981

Affiliations

Indiana University – Purdue University Indianapolis(Current)

Eli Lilly (United States)

Indiana University School of Medicine

Richard L. Roudebush VA Medical Center

University of Washington

Mark A. Deeg is an author at Indiana University – Purdue University Indianapolis specializing in life sciences, medicine, and biochemistry.

ORCID

Publications per year

1981–2020

61

Publications

61

The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes

Gregory Gaich, Jenny Y. Chien, Haoda Fu et al. · Cell Metabolism · 2013 · 879 citations · Full text

, , +11

A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia

Ronald Goldberg, David M. Kendall, Mark A. Deeg et al. · Diabetes Care · 2005 · 795 citations · Full text

, , +14

Ethanol Induces Fatty Acid Synthesis Pathways by Activation of Sterol Regulatory Element-binding Protein (SREBP)

Min You, Monika Fischer, Mark A. Deeg et al. · Journal of Biological Chemistry · 2002 · 545 citations · Full text

, , +17

Systemic Levels of Lipid Peroxidation and Its Metabolic and Dietary Correlates in Patients with Nonalcoholic Steatohepatitis

Naga Chalasani, Mark A. Deeg, David W. Crabb · The American Journal of Gastroenterology · 2004 · 341 citations

, , +17

Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies

Christof Kazda, Ying Ding, Ronan P. Kelly et al. · Diabetes Care · 2015 · 215 citations · Full text

, , +17

1–5 of 61